Safety and Efficacy of Topical Thrombin (Human) Grifols as an Adjunct to Hemostasis During Surgery
|
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. |
| ClinicalTrials.gov Identifier: NCT02014402 |
|
Recruitment Status :
Completed
First Posted : December 18, 2013
Results First Posted : May 10, 2017
Last Update Posted : June 14, 2017
|
Sponsor:
Instituto Grifols, S.A.
Information provided by (Responsible Party):
Grifols Biologicals, LLC ( Instituto Grifols, S.A. )
- Study Details
- Tabular View
- Study Results
- Disclaimer
- How to Read a Study Record
Brief Summary:
This purpose of this clinical trial was to study the safety and efficacy of Topical Thrombin (Human) Grifols as an add-on treatment to help stop bleeding during vascular, liver, soft tissue, and spinal surgical procedures.
| Condition or disease | Intervention/treatment | Phase |
|---|---|---|
| Hemostasis | Biological: Human thrombin Biological: Bovine thrombin | Phase 2 |
This was a prospective, randomized, double-blind, controlled, Phase II study to evaluate the safety and efficacy of Topical Thrombin (Human) Grifols as an adjunct to hemostasis during vascular (IG1202-A), hepatic (IG1202-B), soft tissue (IG1202-C), and spinal (IG1202-D) surgical procedures. Approximately 180 subjects were randomized into 1 of 2 treatment groups in a 2:1 ratio: Topical Thrombin (Human) Grifols (120 subjects) or Bovine Thrombin JMI (60 subjects) among the 4 types of surgeries. Randomized subjects were evaluated for identification of a target bleeding site (TBS) in which control of bleeding by conventional surgical techniques (including suture, ligature and cautery) was ineffective or impractical and required an adjunct treatment to achieve hemostasis. The Investigator rated the intensity of bleeding at the TBS. Topical Thrombin (Human) Grifols or Bovine Thrombin JMI was applied to the TBS and the time to hemostasis was assessed at various timepoints during a 5-minute observation period.
Subjects were evaluated by surgery type and by integrated analysis of clinical studies IG1202-A, IG1202-B, IG1202-C, and IG1202-D.
| Study Type : | Interventional (Clinical Trial) |
| Actual Enrollment : | 181 participants |
| Allocation: | Randomized |
| Intervention Model: | Parallel Assignment |
| Masking: | Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor) |
| Primary Purpose: | Treatment |
| Official Title: | A Prospective, Randomized, Double-blind, Phase II Study to Evaluate the Safety and Efficacy of Topical Thrombin (Human) Grifols as an Adjunct to Hemostasis During Vascular, Hepatic, Soft Tissue, and Spinal Open Surgeries |
| Study Start Date : | December 2013 |
| Actual Primary Completion Date : | November 2015 |
| Actual Study Completion Date : | November 2015 |
Resource links provided by the National Library of Medicine
| Arm | Intervention/treatment |
|---|---|
| Experimental: IG1202-A (Vascular) |
Biological: Human thrombin
Thrombin purified from human plasma reconstituted as a 1000 IU/mL solution in blinded syringes and applied using Gelfoam® sponges Biological: Bovine thrombin Thrombin of bovine origin reconstituted as a 1000 IU/mL solution in blinded syringes and applied using Gelfoam® sponges |
| Experimental: IG1202-B (Hepatic) |
Biological: Human thrombin
Thrombin purified from human plasma reconstituted as a 1000 IU/mL solution in blinded syringes and applied using Gelfoam® sponges Biological: Bovine thrombin Thrombin of bovine origin reconstituted as a 1000 IU/mL solution in blinded syringes and applied using Gelfoam® sponges |
| Experimental: IG1202-C (Soft Tissue) |
Biological: Human thrombin
Thrombin purified from human plasma reconstituted as a 1000 IU/mL solution in blinded syringes and applied using Gelfoam® sponges Biological: Bovine thrombin Thrombin of bovine origin reconstituted as a 1000 IU/mL solution in blinded syringes and applied using Gelfoam® sponges |
| Experimental: IG1202-D (Spinal) |
Biological: Human thrombin
Thrombin purified from human plasma reconstituted as a 1000 IU/mL solution in blinded syringes and applied using Gelfoam® sponges Biological: Bovine thrombin Thrombin of bovine origin reconstituted as a 1000 IU/mL solution in blinded syringes and applied using Gelfoam® sponges |
Primary Outcome Measures :
- Proportion of Subjects Achieving Hemostasis by Five Minutes After Treatment Start at the TBS [ Time Frame: From start of treatment until 5 minutes after treatment start ]Subjects achieving hemostasis at the target bleeding site by 5 minutes following the start of treatment without the occurrence of re-bleeding until the completion of surgical closure
Secondary Outcome Measures :
- Cumulative Proportion of Subjects Having Achieved Hemostasis at the Target Bleeding Site by Specified Time Points [ Time Frame: From start of treatment until 4 minutes after treatment start ]
Cumulative proportion of subjects having achieved hemostasis by each of the following time points:
- At 3 minutes following start of study treatment
- At 4 minutes following start of study treatment
- Prevalence of Treatment Failures [ Time Frame: From start of treatment up to surgical closure by layers of the exposed surgical field containing the TBS, a median of 34 minutes ]Protocol-defined bleeding at the target bleeding site after the start of treatment or the use of alternative hemostatic treatments or maneuvers at the target bleeding site after the start of treatment
Information from the National Library of Medicine
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
| Ages Eligible for Study: | Child, Adult, Older Adult |
| Sexes Eligible for Study: | All |
| Accepts Healthy Volunteers: | No |
Criteria
Inclusion Criteria:
- Pre-operative (at Baseline Assessments Visit) hemoglobin (Hgb) ≥9.0 g/dL (deciliter)
- Pre-operative (at Baseline Assessments Visit) fibrinogen level ≥150 mg/dL (functional method).
-
Required one of the following procedures:
- An elective (non-emergency), open (non-laparoscopic; non- endovascular) surgical procedure involving a native artery-graft end-to-side proximal anastomosis utilizing coated or uncoated polytetrafluoroethylene (PTFE) graft (IG1202-A).
- An elective (non-emergency), open (non-laparoscopic) hepatic resection (anatomic and non-anatomic resections of at least one anatomical hepatic segment or equivalent tissue volume) (IG-1202-B).
- An elective (non-emergency), open (non-laparoscopic), surgical procedure involving soft (non-parenchymous) tissue (IG1202-C).
- An elective (non-emergency), spinal surgical procedure in which the epidural venous plexus was exposed (IG1202-D).
- A target bleeding site (TBS) was identified according to the Investigator's judgment, and the TBS had mild or moderate bleeding according to the Investigator's judgment.
Exclusion Criteria:
- Required surgical procedure due to trauma (except for spinal surgery).
- Infection in the anatomic surgical area.
- History of severe (e.g. anaphylactic) reactions to blood or to any blood-derived (human or animal) product.
- Previous known sensitivity to any Topical Thrombin (Human) Grifols component, any Bovine Thrombin JMI component, porcine collagen, and heparin or protamine (vascular surgery only) component.
- Received an organ transplant.
- Underwent another concurrent major surgical intervention beyond the liver (applied to hepatic surgery [IG1202-B] only; concurrent interventions on the pancreas, gall bladder, bile duct, or intestines were allowed).
- Underwent a re-operative procedure, which was defined as a second, or successive, surgical procedure on the same anatomic location.
- Underwent other vascular procedures during the same surgical session (applied to vascular surgery [IG1202-A] only; stenting and/or endarterectomy of the same artery were allowed).
- Underwent a therapeutic surgical procedure within 30 days from screening (diagnostic procedures were allowed).
- Previously included in this trial (i.e. each subject could only be enrolled once in this study).
- TBS could not be identified according to the investigator's judgment.
- TBS had a severe bleeding according to the Investigator's judgment.
- Occurrence of major intra-operative complications that required resuscitation or deviation from the planned surgical procedure.
- Application of any topical haemostatic material on the resection surface of the liver prior to application of the study treatment (applied to hepatic surgery [IG1202-B] only).
- Radiofrequency precoagulation of the liver resection surface, except focal use of radiofrequency as primary haemostatic treatment (applied to hepatic surgery [IG1202-B] only).
- Intra-operative change in planned surgical procedure which resulted in subject no longer meeting preoperative inclusion and/or exclusion criteria.
- Application of any topical haemostatic material on the cut soft tissue surface prior to application of the study treatment (applied to soft tissue surgery [IG1202-C] only).
Information from the National Library of Medicine
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT02014402
Locations
Show 20 study locations
Sponsors and Collaborators
Instituto Grifols, S.A.
Publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):
| Responsible Party: | Instituto Grifols, S.A. |
| ClinicalTrials.gov Identifier: | NCT02014402 |
| Other Study ID Numbers: |
IG1202 (IG1202-A, -B, -C, -D) |
| First Posted: | December 18, 2013 Key Record Dates |
| Results First Posted: | May 10, 2017 |
| Last Update Posted: | June 14, 2017 |
| Last Verified: | May 2017 |
Keywords provided by Grifols Biologicals, LLC ( Instituto Grifols, S.A. ):
|
Vascular surgery Hepatic surgery Soft tissue surgery Spinal surgery |
Additional relevant MeSH terms:
|
Thrombin Hemostatics Coagulants |